NMTC vs. GUTS, ICAD, ZJYL, MGRM, PTHL, MBOT, FONR, NTRB, INO, and SRTS
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Fractyl Health (GUTS), iCAD (ICAD), Jin Medical International (ZJYL), Monogram Orthopaedics (MGRM), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), Microbot Medical (MBOT), FONAR (FONR), Nutriband (NTRB), Inovio Pharmaceuticals (INO), and Sensus Healthcare (SRTS). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs. Its Competitors
Fractyl Health (NASDAQ:GUTS) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.
Fractyl Health has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
NeuroOne Medical Technologies received 59 more outperform votes than Fractyl Health when rated by MarketBeat users. However, 100.00% of users gave Fractyl Health an outperform vote while only 71.91% of users gave NeuroOne Medical Technologies an outperform vote.
NeuroOne Medical Technologies has higher revenue and earnings than Fractyl Health. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 8.9% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Fractyl Health and Fractyl Health both had 1 articles in the media. Fractyl Health's average media sentiment score of 1.87 beat NeuroOne Medical Technologies' score of 0.93 indicating that Fractyl Health is being referred to more favorably in the media.
NeuroOne Medical Technologies has a net margin of -82.17% compared to Fractyl Health's net margin of -64,849.48%. Fractyl Health's return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.
Fractyl Health currently has a consensus price target of $11.00, indicating a potential upside of 384.58%. NeuroOne Medical Technologies has a consensus price target of $1.45, indicating a potential upside of 156.68%. Given Fractyl Health's higher probable upside, research analysts plainly believe Fractyl Health is more favorable than NeuroOne Medical Technologies.
Summary
Fractyl Health beats NeuroOne Medical Technologies on 9 of the 16 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy NMTC Stock Free NMTC Stock Alerts